**MiR-216a-5p alleviates LPS-induced inflammation in the human bronchial epithelial cell by inhibition of TGF-β1 signaling via down-regulating TGFBR2**

Shan Liu\textsuperscript{a}, Jianjun Li\textsuperscript{b}, Liya Hu\textsuperscript{b}\textsuperscript{*}

\textsuperscript{a}Department of Pediatrics, Zhejiang Quhua Hospital, Quhua City, Zhejiang Province, 324004, China
\textsuperscript{b}Department of Pediatrics, Lishui Peoples Hospital, Lishui City, Zhejiang Province, 323000, China

Received 2 June 2021; Accepted 29 July 2021
Available online 1 September 2021

**Abstract**

**Objective:** Bronchopneumonia is a common respiratory infection disease and is the leading cause of hospitalization in children under 5 years of age. Inflammation is the primary response caused by bronchopneumonia. But the detailed underlying mechanism of inflammation in bronchopneumonia remains unclear. Therefore, this study focused on studying the effect of miR-216a-5p on inflammation induced by bronchopneumonia and investigating the potential mechanism underlying it.

**Methods:** Human bronchial epithelial cells (BEAS-2B) were stimulated using lipopolysaccharides (LPS) to trigger bronchopneumonia in vitro. The production of interleukin (IL)-1β, IL-6, and Tumor necrosis factor (TNF)-α was measured using the enzyme-linked immunosorbent assay. The luciferase assay was conducted to explore the relationship between miR-216a-5p and TGFBR2. Quantitative real-time polymerase chain reaction and western blot were used to detect the gene expression.

**Results:** miR-216a-5p gene expression decreased in BEAS-2B cells stimulated by LPS. Overexpression of miR-216a-5p suppressed the elevated levels of IL-1β, IL-6, and TNF-α induced by LPS. Transforming growth factor-beta receptor 2 (TGFBR2) proved to be a direct target of miR-216a-5p, and they negatively modulated TGFBR2 expression. In addition, overexpression of miR-216a-5p inhibited LPS-induced protein levels of TGFBR2, transforming growth factor (TGF)-β1, and phosphorylation of SMAD family member 2 (smad2). This ectopic expression of miR-216a-5p was restored by overexpressed TGFBR2.

**Conclusion:** miR-216a-5p was decreased in LPS-stimulated BEAS-2B cells. Overexpressed miR-216a-5p suppressed LPS-induced inflammation in BEAS-2B cells by inhibition of TGF-β1 signaling via down-regulating TGFBR2. miR-216a-5p may be a valuable target for anti-inflammation treatment in bronchopneumonia.

**KEYWORDS**
bronchopneumonia; inflammation; miR-216a-5p; TGFBR2; TGFβ1 signaling

*Corresponding author: Liya Hu, Department of Pediatrics, Lishui Peoples Hospital, Lishui, Zhejiang Province, 323000, China. Email address: huliya_666@163.com

https://doi.org/10.15586/aei.v49i5.458
Copyright: Shan L, et al.
License: This open access article is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). http://creativecommons.org/
Bronchopneumonia is a common respiratory infection disease and is the main cause of hospitalization in children under 5 years of age. Inflammation is a primary response caused by bronchopneumonia. But the detailed underlying mechanism of inflammation in bronchopneumonia remains unclear. Therefore, this study focused on studying the effect of miR-216a-5p on inflammation caused by bronchopneumonia and investigate the potential mechanism underlying it. In this study, human bronchial epithelial cells (BEAS-2B) were stimulated using lipopolysaccharides (LPS) to trigger bronchopneumonia in vitro. miR-216a-5p was decreased in BEAS-2B cells stimulated by LPS. Overexpression of miR-216a-5p suppressed the elevated levels of interleukin (IL)-1β, IL-6, and Tumor necrosis factor (TNF)-α induced by LPS. Transforming growth factor-beta 2 (TGFB2) proved to be a direct target of miR-216a-5p, and they negatively modulated TGFB2 expression. In addition, overexpression of miR-216a-5p inhibited LPS-induced protein levels of TGFB2, transforming growth factor-beta 1 (TGF-β1), and phosphorylation of SMAD family member 2 (smad2). This ectopic overexpression of miR-216a-5p was restored by overexpressed TGFB2. In conclusion, miR-216a-5p was decreased in LPS-stimulated BEAS-2B cells. Overexpressed miR-216a-5p suppressed LPS-induced inflammation in BEAS-2B cells by inhibition of TGF-β1 signaling via down-regulating TGFB2. miR-216a-5p may be a valuable target for anti-inflammation treatment in bronchopneumonia.

© 2021 Codon Publications. Published by Codon Publications.

Introduction

Bronchopneumonia is a frequent respiratory infection disease in children under 5 years of age. It is the most common hospitalization reason, and is one of the critical death causes for children. In China, the mortality rate is approximately 184 to1223/100,000 for children under 5 years. The common triggers causing bronchopneumonia are the infection of bacteria, viruses, mycoplasma, and other pathogens. Children are more susceptible to this infection because of the dysfunctional immune system. Increasing evidence revealed that inflammation is the primary response caused by bronchopneumonia infection, which indicates that anti-inflammation treatment may be an effective therapeutic strategy for bronchopneumonia. However, the potential mechanism of inflammation during bronchopneumonia remains unclear at present. Hence, it is imperative to investigate the detailed mechanism of inflammation underlying it.

MicroRNAs (miRNAs) are small noncoding RNAs with 18-25 nucleotides in length. In recent years, miRNAs have been proved to regulate many diseases including pneumonia, by repressing the expression of target genes. For example, Zhang et al. revealed that miR-146b alleviated the inflammation injury in pediatric pneumonia by regulating MyD88/NF-κB signaling pathway. In acute pneumonia, miR-370-3p modulated lipopolysaccharides (LPS)-induced WI-38 cell apoptosis and inflammation by binding to the toll-like receptor 4 (TLR4). miR-455-5p inhibited M1 macrophage polarization by binding to the suppressor of cytokine signaling 3 (SOCS3) in childhood pneumonia. In addition, miR-218 suppressed LPS-induced bronchial epithelial cell injury through targeting E2F Transcription Factor 2 (E2F2) in bronchopneumonia.

As a member of the miRNAs family, miR-216a-5p is demonstrated to involve in some diseases. For instance, they attenuate oxidative stress caused by hydrogen peroxide via modulating the HMGB1/NF-κB pathway in human bronchial epithelial cell line 16HBE. miR-216a-5p inhibited tumor progression via binding to TPT1/mTORC1 in pancreatic cancer. Furthermore, accumulating evidence revealed that miR-216a-5p modulated inflammation response in some diseases. Kong et al. reported that miR-216a attenuated LPS-induced inflammatory injury through modulating JAK2/STAT3 and NF-κB signaling pathways in acute lung injury. Peng et al. reported that miR-216a-5p-containing exosomes suppressed rTfp17-caused inflammatory via binding to TLR4. However, the action of miR-216a-5p on bronchopneumonia is not elucidated at present. Given the regulatory effect of miR-216a-5p on inflammation response, it was inferred that miR-216a-5p might affect bronchopneumonia development. Hence, this study focuses on investigating the action of miR-216a-5p on bronchopneumonia and study the detailed mechanism underlying it.

Materials and methods

Cell culture

Human bronchial epithelial cell line BEAS-2B was acquired from American Type Culture Collection (ATCC, Manassas, VA) and maintained in Dulbecco’s Modified Eagle medium with 10% fetal bovine serum at 37°C with 5% carbon-di-oxide. Later, cells were stimulated with LPS of 1, 5, 10, 20, or 30 μM, respectively (Sigma, St. Louis, MO, USA) for 6, 12, 24, or 48 hours.

Quantitative real-time polymerase chain reaction (qRT-PCR)

RNA of BEAS-2B cells were isolated using TRIzol (Sigma). Complementary DNA was generated through reverse transcription using the Sensiscript II reverse transcriptase (Qiagen, Hilden, Germany), followed by a qPCR assay using SYBR Green PCR master mix (Qiagen, Hilden, Germany). The primers used in the study were: miR-216a-5p: F, 5’-ACGGCGTTACAGTGTTTCTG-3’; R, 5’-GCACATACAAAAGTATCTACATCCTCGACGG-3’. 3α: F, 5’-GTAGGGCGATTACAGTCACGG-3’; R, 5’-GGAAGGTTCAGGTTGTTTTCTGC-3’. 3β: F, 5’-TAATGCTGATTTAGTAGTATTTCTGACGG-3’. IL-6: F, 5’-AAATTCGGTCTTATGGATGTA-3’; R, 5’-GGATATGGAGCAACAAGTGG-3’. IL-8: F, 5’-GGATATGGAGCAACAAGTGG-3’; R, 5’-GGATATGGAGCAACAAGTGG-3’. TNF-α: F, 5’-GGATATGGAGCAACAAGTGG-3’; R, 5’-GGATATGGAGCAACAAGTGG-3’. The primers used in the study were: miR-216a-5p: F, 5’-TGTCGCAAATCTCTGCAGG-3’. R, 5’-CAGAGCAGGGTCCGAGG-3’. The primers used in the study were: miR-216a-5p: F, 5’-TGTCGCAAATCTCTGCAGG-3’. R, 5’-CAGAGCAGGGTCCGAGG-3’.
CGGCCTATCTC-3', 19 β-actin and U6 served as control genes for data normalization. Relative gene expression was analyzed by the 2^ΔΔCt method. 

**Enzyme-linked immunosorbent assay (ELISA)**

The production of IL-1β, IL-6, and TNF-α in BEAS-2B cells were determined using the corresponding human ELISA kit (R&D Systems, Inc., Minneapolis, MN, USA) following instructions of the manufacturer.

**Luciferase assay**

Bioinformatics analysis for miR-216a-5p targets was conducted using Targetscan (http://www.targetscan.org/). The wild and mutant sequences of TGFBR2 targeting miR-216a-5p were fused into the pmirGLO vector (Promega, Madison, WI, USA). The cloned pmirGLO vector and miR-216a-5p mimic were transfected into BEAS-2B cells. Forty-eight hours post transfection, a dual-luciferase reporter assay system (Promega, Madison, WI, USA) was employed to measure luciferase activity.

**Cell transfection**

miR-216a-5p mimic and TGFBR2 overexpressed plasmid were acquired from Sangon Biotech (Sangon Biotech, Shanghai, China) and were transfected into BEAS-2B cells utilizing Lipofectamine 3000 (Thermo Scientific, Waltham, MA, USA) following the instructions of the manufacturer. Forty-eight hours post-transfection, the cells were exposed to 10 μM LPS for 48 hours.

**Western blot**

Total protein extraction from BEAS-2B cells was conducted utilizing radioimmunoprecipitation assay buffer and quantified using a BCA kit (Sigma). Extracted proteins were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred onto a polyvinylidene fluoride membrane. After blocking for nonspecific binding, the membrane was labeled with anti-TGFBR2 (1:2000; ab186838), TGF-β1 (1:2000; ab92486), p-SMAD family member 2 (smad2; 1:2000; ab188334), smad2 (1:2000; ab228765), and β-actin (1:3000) antibodies (Abcam, Cambridge, MA, UK) at 4°C for 12 h. Then, they were further treated with goat anti-mouse IgG H&L (Abcam, Cambridge, MA, UK) for 2 hours. β-actin was chosen as the control protein. The blots were studied using the ECL Plus Western Blotting Substrate (Thermo Fisher Scientific, Waltham, MA, USA).

**Statistical analysis**

Data were described as mean ± standard deviation (SD), and data processing was conducted by SPSS Statistics 22.0 (SPSS, Chicago, IL, USA). One-way analysis of variance with the least significant difference post hoc test was applied for multiple group comparisons. P < 0.05 was the principle of statistical significance.

**Results**

**miR-216a-5p expression decreased in LPS-induced BEAS-2B cells**

To interpret the action of miR-216a-5p on the bronchopneumonia of children. BEAS-2B cells were first exposed to LPS to imitate the bronchopneumonia cell model. Later, miR-216a-5p expression in LPS-induced BEAS-2B was determined. miR-216a-5p was down-regulated in BEAS-2B cells after being stimulated with 1, 5, 10, 20, or 30 μM LPS, respectively, for 48 hours (P < 0.01; Figure 1A). Especially, miR-216a-5p presented the lowest expression in BEAS-2B cells stimulated by 10 μM LPS (Figure 1A). Therefore, 10 μM LPS was selected to induce BEAS-2B cells in the follow-up experiments. In addition, miR-216a-5p expression decreased in BEAS-2B cells after 10 μM LPS treatment in a time-dependent manner (P < 0.01; Figure 1B). Therefore, miR-216a-5p was down-regulated in LPS-stimulated BEAS-2B cells.

**miR-216a-5p expression suppressed LPS-induced inflammation in BEAS-2B cells**

For better exploration of the role of miR-216a-5p in bronchopneumonia, miR-216a-5p mimic was introduced into BEAS-2B cells to imitate the bronchopneumonia cell model. Later, miR-216a-5p expression in LPS-induced BEAS-2B was determined. miR-216a-5p was down-regulated in BEAS-2B cells after being stimulated with 1, 5, 10, 20, or 30 μM LPS, respectively, for 48 hours (P < 0.01; Figure 1A). Especially, miR-216a-5p presented the lowest expression in BEAS-2B cells stimulated by 10 μM LPS (Figure 1A). Therefore, 10 μM LPS was selected to induce BEAS-2B cells in the follow-up experiments. In addition, miR-216a-5p expression decreased in BEAS-2B cells after 10 μM LPS treatment in a time-dependent manner (P < 0.01; Figure 1B). Therefore, miR-216a-5p was down-regulated in LPS-stimulated BEAS-2B cells.
This study investigated if the TGF-β1 signaling pathway was associated with the modulation of miR-216a-5p on LPS-caused inflammation. After BEAS-2B cells were introduced into miR-216a-5p mimic and TGFBR2 overexpression plasmid and treated with LPS, the protein levels of TGFBR2, TGF-β1, and phosphorylation of smad2 were detected. Results revealed that miR-216a-5p mimic restrained LPS-induced protein levels of TGFBR2 and TGF-β1, which was seen to be reversed by overexpressed TGFBR2 (P < 0.01; Figure 4). In addition, LPS induced phosphorylation of smad2 was repressed by miR-216a-5p mimic and was observed to be reversed by overexpressed TGFBR2 later (P < 0.01; Figure 4). Hence, miR-216a-5p suppressed the TGF-β1 signaling pathway through modulating TGFBR2.

miR-216a-5p inhibited the TGF-β1 signaling pathway by modulating TGFBR2

Previous studies reported that the TGF-β1 signaling participated in pulmonary inflammation regulation.21,22 This study investigated if the TGF-β1 signaling pathway was associated with the modulation of miR-216a-5p on LPS-caused inflammation. After BEAS-2B cells were introduced into miR-216a-5p mimic and TGFBR2 overexpression plasmid and treated with LPS, the protein levels of TGFBR2, TGF-β1, and phosphorylation of smad2 were detected. Results revealed that miR-216a-5p mimic restrained LPS-induced protein levels of TGFBR2 and TGF-β1, which was seen to be reversed by overexpressed TGFBR2 (P < 0.01; Figure 4). In addition, LPS induced phosphorylation of smad2 was repressed by miR-216a-5p mimic and was observed to be reversed by overexpressed TGFBR2 later (P < 0.01; Figure 4). Hence, miR-216a-5p suppressed the TGF-β1 signaling pathway through modulating TGFBR2.

Thus, miR-216a-5p suppressed LPS-induced inflammation in BEAS-2B cells.

TGFBR2 was a target of miR-216a-5p

To investigate the mechanism of miR-216a-5p alleviating LPS-caused inflammation in BEAS-2B cells, the underlying targets of miR-216a-5p were screened by bioinformatics analysis. Using the Targetscan database, TGFBR2 was found to be a target of miR-216a-5p, and the potential target sequence of TGFBR2 and miR-216a-5p are listed in Figure 3A. Later, a luciferase assay was performed to verify the relationship between miR-216a-5p and TGFBR2. Results proved that miR-216a-5p mimic caused a noticeable reduction in the activity of wild 3'-UTR of TGFBR2 reporter but did not affect mutant 3'-UTR of TGFBR2 reporter (P < 0.01; Figure 3B). Besides, qRT-PCR results revealed that LPS induced TGFBR2 mRNA expression but was inhibited by miR-216a-5p mimic (P < 0.01; Figure 3C). Furthermore, Western blot results found that the promotional effect of LPS on the TGFBR2 protein level was remarkably abolished by miR-216a-5p mimic (P < 0.01, Figure 3D). In conclusion, TGFBR2 was a direct target of miR-216a-5p, and it negatively regulated TGFBR2 expression.

miR-216a-5p suppressed LPS-induced inflammation in BEAS-2B cells via regulating TGFBR2

To investigate the underlying mechanism of the regulation of miR-216a-5p on LPS-induced inflammation. The BEAS-2B cells were cotransfected with miR-216a-5p mimic and TGFBR2 overexpression plasmid and treated with LPS. The expression levels of IL-1β, IL-6, and TNF-α were then determined. Results showed that miR-216a-5p mimic suppressed LPS-induced mRNA levels of IL-1β, IL-6, and TNF-α, which were seen to be restored by overexpressed TGFBR2 (P < 0.01; Figure 5). Therefore, these findings suggested that miR-216a-5p suppressed LPS-induced inflammation in BEAS-2B cells via TGFBR2 regulation.
Shan Liu, et al. was explored. Results revealed that overexpressed miR-216a-5p suppressed the secretion of IL-1β, IL-6, and TNF-α caused by LPS in BEAS-2B cells. The regulatory effect of miR-216a-5p on inflammation response has already been reported in other diseases.\textsuperscript{14,24} Pent et al.\textsuperscript{14} revealed that decreased miR-216a-5p in syphilis patients was negatively associated to the levels of IL-1β, IL-6, and TNF-α, and miR-216a-5p-containing exosomes alleviated rTp17-caused inflammation. Similarly, Wang et al.\textsuperscript{24} revealed that overexpressed miR-216a-5p inhibited the levels of IL-6, TNF-α, and IL-1β in neuropathic pain caused by chronic constriction injury. Overall, these findings indicated that miR-216a-5p suppressed LPS-caused inflammation in BEAS-2B cells.

Accumulating evidence demonstrated that miRNAs usually played a regulatory role in diseases by binding to the target gene.\textsuperscript{25} Therefore, to elucidate the potential mechanism of miR-216a-5p on LPS-caused inflammation in BEAS-2B cells, the targets of miR-216a-5p were searched. The findings revealed that TGFBR2 was the target of miR-216a-5p, and it negatively modulated the TGFBR2 expression. This target relation of TGFBR2 and miR-216a-5p has not been reported. TGFBR2 is a transmembrane serine/threonine kinase, and it is the critical member of the TGF-β\textsuperscript{1} signaling pathway.\textsuperscript{26,27} A previous study proved that suppressing TGFBR2 inhibited TGF-β1 signal transduction, thereby alleviating inflammation response and apoptosis in the model of bronchopulmonary dysplasia.\textsuperscript{21} In addition, LPS could cause endogenous bioactive factors production, thereby triggering inflammation response.\textsuperscript{5,21} Therefore, LPS was used to treat BEAS-2B cells to simulate bronchopneumonia in vitro. miR-216a-5p expression was determined in BEAS-2B cells stimulated by LPS. The study outcomes revealed that miR-216a-5p declined in LPS-treated BEAS-2B cells, which was in line with the Kong et al. study.\textsuperscript{13} They showed that miR-216a-5p expression decreased in acute lung injury caused by LPS.\textsuperscript{13} The aberrant expression of miR-216a-5p in BEAS-2B cells exposed to LPS indicated that it might exert a regulation role in bronchopneumonia. To investigate the action of miR-216a-5p on bronchopneumonia, the effect of the miR-216a-5p expression on inflammatory cytokines secretion was explored. Results revealed that overexpressed miR-216a-5p suppressed the secretion of IL-1β, IL-6, and TNF-α caused by LPS in BEAS-2B cells.

Discussion

As a common respiratory infection disease, bronchopneumonia is the leading cause of hospitalization in children.\textsuperscript{1,2} At present, anti-inflammation treatment may be an effective therapeutic strategy for bronchopneumonia because it causes inflammation response.\textsuperscript{3,4} However, the potential mechanism of inflammation response in bronchopneumonia has not been fully elucidated. miR-216a-5p is proved to modulate inflammation response,\textsuperscript{14} whereas its effect on bronchopneumonia was unclear. Therefore, this study explored the action of miR-216a-5p on bronchopneumonia in this study.

Studies revealed that LPS could cause endogenous bioactive factors production, thereby triggering inflammation response.\textsuperscript{5,21} Therefore, LPS was used to treat BEAS-2B cells to simulate bronchopneumonia in vitro. miR-216a-5p expression was determined in BEAS-2B cells stimulated by LPS. The study outcomes revealed that miR-216a-5p declined in LPS-treated BEAS-2B cells, which was in line with the Kong et al. study.\textsuperscript{13} They showed that miR-216a-5p expression decreased in acute lung injury caused by LPS.\textsuperscript{13} The aberrant expression of miR-216a-5p in BEAS-2B cells exposed to LPS indicated that it might exert a regulation role in bronchopneumonia. To investigate the action of miR-216a-5p on bronchopneumonia, the effect of the miR-216a-5p expression on inflammatory cytokines secretion was explored. Results revealed that overexpressed miR-216a-5p suppressed the secretion of IL-1β, IL-6, and TNF-α caused by LPS in BEAS-2B cells. The regulatory effect of miR-216a-5p on inflammation response has already been reported in other diseases.\textsuperscript{14,24} Pent et al.\textsuperscript{14} revealed that decreased miR-216a-5p in syphilis patients was negatively associated to the levels of IL-1β, IL-6, and TNF-α, and miR-216a-5p-containing exosomes alleviated rTp17-caused inflammation. Similarly, Wang et al.\textsuperscript{24} revealed that overexpressed miR-216a-5p inhibited the levels of IL-6, TNF-α, and IL-1β in neuropathic pain caused by chronic constriction injury. Overall, these findings indicated that miR-216a-5p suppressed LPS-caused inflammation in BEAS-2B cells.

Accumulating evidence demonstrated that miRNAs usually played a regulatory role in diseases by binding to the target gene.\textsuperscript{25} Therefore, to elucidate the potential mechanism of miR-216a-5p on LPS-caused inflammation in BEAS-2B cells, the targets of miR-216a-5p were searched. The findings revealed that TGFBR2 was the target of miR-216a-5p, and it negatively modulated the TGFBR2 expression. This target relation of TGFBR2 and miR-216a-5p has not been reported. TGFBR2 is a transmembrane serine/threonine kinase, and it is the critical member of the TGF-β\textsuperscript{1} signaling pathway.\textsuperscript{26,27} A previous study proved that suppressing TGFBR2 inhibited TGF-β1 signal transduction, thereby alleviating inflammation response and apoptosis in the model of bronchopulmonary dysplasia.\textsuperscript{21} In addition,
MiR-216a-5p alleviates LPS-induced inflammation

MiR-216a-5p alleviates LPS-induced inflammation 69

regulate TGF-β1 signaling in bronchopneumonia. The outcomes showed that overexpressed miR-216a-5p restrained LPS-induced protein levels of TGFBR2, TGF-β1, and phosphorylation of smad2, which was seen to be reversed by overexpressed TGFBR2. In other words, miR-216a-5p

other researches showed that the TGF-β1 signaling participated in the regulation of pulmonary inflammation, and its expression was elevated in the bronchoalveolar lavage fluid of patients with idiopathic eosinophilic pneumonia. Thus, this study inferred that miR-216a-5p might also regulate TGF-β1 signaling in bronchopneumonia. The outcomes showed that overexpressed miR-216a-5p restrained LPS-induced protein levels of TGFBR2, TGF-β1, and phosphorylation of smad2, which was seen to be reversed by overexpressed TGFBR2. In other words, miR-216a-5p
suppressed the TGF-β1 signaling pathway through modulating TGFBR2. Furthermore, the investigation of the underlying mechanism of miR-216a-5p on LPS-induced inflammation in the human bronchial epithelial cell revealed that miR-216a-5p suppressed LPS-induced inflammation in BEAS-2B cells via regulating TGFBR2. Thus, this study hypothesized that the following regulatory pathway in bronchopneumonia: LPS stimulation induced a decrease in miR-216a-5p expression, and this miR-216a-5p elevated TGFBR2 expression, thereby activating the TGF-β1 signaling pathway, which induced inflammatory factor production and consequently bronchopneumonia. (Figure 6). Additionally, ectopic expression of miR-216a-5p alleviated LPS-induced inflammation in the human bronchial epithelial cell by inhibiting TGF-β1 signaling via down-regulating TGFBR2.

**Conclusion**

miR-216a-5p suppressed LPS-induced inflammation in BEAS-2B cells by the inhibition of TGFβ1 signaling via down-regulating TGFBR2. miR-216a-5p may be a valuable target for anti-inflammation treatment in bronchopneumonia.

**Conflict of interest**

No potential conflict of interest was reported by the author.

**References**


